Constipation Treatment Market By Product Type (Mu-Opioid Receptor Antagonists, Laxative, Chloride Channel-2 Activator, Guanylate Cyclase-C (GC-C) Agonist, Others), By Disease Type (Opioid-Induced Constipation, Chronic Idiopathic Constipation, Irritable Bowel Syndrome with Constipation), By Prescription Type (Prescribed Drugs, Over-the-Counter Drugs), By Distribution Channel (Online Pharmacy, Drug Store and Retail Pharmacy, Others): Global Opportunity Analysis and Industry Forecast, 2023-2032

Constipation Treatment Market

Chronic constipation is infrequent bowel movements or difficulty in passage of stools that persists for several weeks or longer. Constipation is generally described as having fewer than three bowel movements a week. Signs and symptoms of chronic constipation include having lumpy or hard stools, straining to have bowel movements, and feeling as though there is a blockage in the rectum that prevents bowel movements.

There are different types of drugs used for constipation treatment such as opioid antagonist, laxative, chloride channel-2 activator, guanylate cyclase-C (GC-C) agonist, and others such as selective 5-ht agonists and sodium-proton-exchanger subtype 3 (NHE3) inhibitor. The disease types of constipation include opioid-induced constipation, chronic idiopathic constipation, and irritable bowel syndrome with constipation (IBS-C). Prescription type for constipation treatment includes prescribed drugs and over-the-counter drugs. Distribution channel for constipation drugs are online pharmacy, drug store & retail pharmacy and others which includes hospital pharmacies and general stores.

Key factors driving the growth of the constipation treatment market include rise in prevalence of chronic diseases such as cancer, high presence of market players, and surge in number of geriatric populations. Moreover, increase in number of adoptions of key strategies such as business expansion, partnership, agreement and others are anticipated to boost the growth of market. For instance, in February 2022, Ardelyx, Inc., a biopharmaceutical company, announced that it has entered into a debt financing agreement with investment affiliates managed by SLR Capital Partners (SLR). This agreement includes the launch and commercialization of IBSRELA for the treatment of irritable bowel syndrome with constipation in adults. This financing further strengthens the balance sheet and extends the cash runway offering operational flexibility to further support the launch of IBSRELA.

In addition, Rise in prevalence of opioid induced constipation and increase in number of product provision for opioid antagonist are anticipated to boost the growth of market. For instance, the opioid antagonist commonly used in treatment of opioid induced constipation are Relistor by Salix Pharma (Bausch Health), Moventig (naloxegol) by AstraZeneca plc., and Movantik by Cosmo Pharmaceuticals. Moreover, high presence of market players who manufacture opioid antagonists and rise in the number of product launches for opioid antagonists are anticipated to boost growth of the constipation treatment market.

Moreover, increase in prevalence of chronic idiopathic constipation and rise in availability of laxatives for treatment of constipation are anticipated to drive the growth of market. For instance, Duphalac by Abbott, a pharmaceutical company, Dilcoflex by Sanofi, and MiraLAX by Bayer AG are some laxatives used in the treatment of chronic idiopathic constipation. Moreover, rise in prevalence of constipation is expected to drive the growth of market. For instance, according to report published by National Library of Medicine, in July 2023, a systematic literature review revealed that constipation has a global prevalence of approximately 14.0%. Thus, increase in prevalence of constipation, rise in number of product launches, and high presence of market players are anticipated to boost the growth of market.

The constipation treatment market is segmented based on product type, disease type, prescription type, distribution channel, and region. By product type, the market is classified into Mu-opioid receptor antagonists, laxative, chloride channel-2 activator, guanylate cyclase-C (GC-C) agonist, and others. Others includes selective 5-ht agonists and sodium-proton-exchanger subtype 3 (NHE3) inhibitor. As per disease type, the constipation treatment market is segmented into opioid-induced constipation, chronic idiopathic constipation, and irritable bowel syndrome with constipation. According to prescription type, the market is classified into prescribed drugs and over-the-counter drugs. By distribution channel, the market is divided into online pharmacy, drug store & retail pharmacy and others. Others includes hospital pharmacies and general stores.

Region-wise, the market is analyzed across North America, Europe, Asia-Pacific, and LAMEA. Region wise, it is analyzed across North America (the U.S., Canada, and Mexico), Europe (the UK, Germany, France, Italy, Spain, and rest of Europe), Asia-Pacific (China, India, Japan, Australia, South Korea and rest of Asia-Pacific), and LAMEA (Brazil, Saudi Arabia, South Africa, and rest of LAMEA).

The key players profiled in the study Salix Pharma (Bausch Health), Takeda Pharmaceutical, AbbVie, Abbott, Sanofi, Bayer AG, AstraZeneca plc., Ironwood Pharmaceuticals, Inc., Prestige Consumer Healthcare Inc. and Ardelyx. The players in the market have been actively engaged in the adoption various strategies such as acquisition, product launch and expansion to remain competitive and gain advantage over the competitors in the market.

Key Market Insights

By product type, laxative segment was the highest revenue contributor to the market and is estimated to reach $ 3755.67 million by 2032, with a CAGR of 4.9%.

By disease type, the chronic idiopathic constipation segment dominated the global market. However, the opioid-induced constipation segment is expected to be the fastest-growing segment with a CAGR of 6.2% during the forecast period.

By prescription type, the prescribed drugs segment dominated the global market. However, the over-the-counter drugs segment is expected to be the fastest-growing segment with a CAGR of 5.9% during the forecast period.

By distribution channel, the drug store and retail pharmacy segment dominated the global market. However, the online pharmacy segment is expected to be the fastest-growing segment with a CAGR of 6.3% during the forecast period.

Based on region, North America garnered the largest revenue share in 2022, whereas Asia-Pacific is anticipated to grow at the highest CAGR of 6.4% during the forecast period

Overview

The Constipation Treatment Market was valued for $5,888.08 million in 2022 and is estimated to reach $10,122.69 million by 2032, exhibiting a CAGR of 5.6% from 2023 to 2032. Constipation occurs when your bowel movements become less frequent, and stools become difficult to pass. It happens most often due to changes in diet or routine, or due to inadequate intake of fiber. Symptoms include hard stools, stomach cramps, bloating, and nausea. People with long-term constipation can develop hemorrhoids (piles), fecal impaction where dry, hard stools collect in the rectum, and bowel incontinence (the leakage of liquid stools).

The constipation treatment market growth is driven by high presence of market players who manufacture constipation treatment products, rise in prevalence of constipation, and increase in use of opioids for pain management. The well-known side effects of opioids are their impact on the gastrointestinal system, often causing constipation. This effect occurs due to the way opioids interact with receptors in the gastrointestinal tract and the nervous system. Thus, rise in population suffering from chronic pain is anticipated to drive the use of pain killers. Therefore, this factor is anticipated to increase in prevalence of constipation and boost the growth of market. For instance, according to U.S. Chronic Pain Foundation, in 2022, 50 million Americans live with chronic pain, or pain that lasts most days or every day for three months or more. More than half (52%) said their average pain level is 7 or more on a scale of 1-10.

Moreover, rising incidence of constipation, often linked to sedentary lifestyles, poor dietary habits, and stress, is a primary driver for the growth of the constipation treatment market. Changes in dietary habits, including a shift toward processed foods with lower fiber content, can contribute to constipation. This drives the demand for treatments to alleviate its symptoms. In addition, stress and mental health issues can impact digestive processes, including bowel movements. Thus, unhealthy lifestyle factors are anticipated to increase in prevalence of constipation and drive the growth of market. 

In addition, rise in number of geriatric populations is anticipated to drive the growth of the constipation treatment market. As people age, the digestive system tends to slow down, including the movement of food and waste through the intestines. This slower transit time can lead to the accumulation of stool in the colon and contribute to constipation. Thus, rise in number of geriatric populations is anticipated to increase in prevalence of constipation. For instance, according to World Health Organization (WHO), it was estimated that, by 2030, 1 in 6 people in the world will be aged 60 years or over. At this time, the share of the population aged 60 years and over will increase from 1 billion in 2020 to 1.4 billion. By 2050, the world’s population of people aged 60 years and older will double (2.1 billion). The number of persons aged 80 years or older is expected to triple between 2020 and 2050 to reach 426 million. Moreover, according to Frontiers in Public Health, in 2022, it was reported that, the prevalence of constipation was 17.60% in elderly people aged 65 years and old.

The constipation treatment market is segmented based on product type, disease type, prescription type, distribution channel, and region. By product type, the market is classified into Mu-opioid receptor antagonists, laxative, chloride channel-2 activator, guanylate cyclase-C (GC-C) agonist, and others. Others includes selective 5-ht agonists and sodium-proton-exchanger subtype 3 (NHE3) inhibitor. As per disease type, the constipation treatment market is segmented into opioid-induced constipation, chronic idiopathic constipation, and irritable bowel syndrome with constipation. According to prescription type, the market is classified into prescribed drugs and over-the-counter drugs. By distribution channel, the market is divided into online pharmacy, drug store & retail pharmacy and others. Others includes hospital pharmacies and general stores.

Region-wise, the market is analyzed across North America (U.S., Canada, and Mexico), Europe (Germany, France, UK, Italy, Spain, and rest of Europe), Asia-Pacific (China, Japan, India, Australia, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, Saudi Arabia, South Africa, and rest of LAMEA).

Major key players that operate in the global constipation treatment market are Salix Pharma (Bausch Health), Takeda Pharmaceutical, AbbVie, Abbott, Sanofi, Bayer AG, AstraZeneca plc., Ironwood Pharmaceuticals, Inc., Prestige Consumer Healthcare Inc. and Ardelyx. Key players operating in the market have adopted product approval, product launch, acquisition, and agreement as their key strategies to expand their constipation treatment market share.

Key Benefits For Stakeholders

●This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the constipation treatment market analysis from 2022 to 2032 to identify the prevailing constipation treatment market opportunities.

●The market research is offered along with information related to key drivers, restraints, and opportunities.

●Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.

●In-depth analysis of the constipation treatment market segmentation assists to determine the prevailing market opportunities.

●Major countries in each region are mapped according to their revenue contribution to the global market.

●Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.

●The report includes the analysis of the regional as well as global constipation treatment market trends, key players, market segments, application areas, and market growth strategies.

Additional benefits you will get with this purchase are:

● Quarterly Update and* (only available with a corporate license, on listed price)

● 5 additional Company Profile of client Choice pre- or Post-purchase, as a free update.

● Free Upcoming Version on the Purchase of Five and Enterprise User License.

● 16 analyst hours of support* (post-purchase, if you find additional data requirements upon review of the report, you may receive support amounting to 16 analyst hours to solve questions, and post-sale queries)

● 15% Free Customization* (in case the scope or segment of the report does not match your requirements, 20% is equivalent to 3 working days of free work, applicable once)

● Free data Pack on the Five and Enterprise User License. (Excel version of the report)

● Free Updated report if the report is 6-12 months old or older.

● 24-hour priority response*

● Free Industry updates and white papers.

Possible Customization with this report (with additional cost and timeline talk to the sales executive to know more)

● Product Benchmarking / Product specification and applications

○ AbbVie Inc

Scope of Constipation Treatment Market Report

1.1. Report description

1.2. Key market segments

1.3. Key benefits to the stakeholders

1.4. Research Methodology

1.4.1. Primary research

1.4.2. Secondary research

1.4.3. Analyst tools and models

2.1. CXO Perspective

3.1. Market definition and scope

3.2. Key findings

3.2.1. Top impacting factors

3.2.2. Top investment pockets

3.3. Porter’s five forces analysis

3.3.1. Low bargaining power of suppliers

3.3.2. Low threat of new entrants

3.3.3. Low threat of substitutes

3.3.4. Low intensity of rivalry

3.3.5. Low bargaining power of buyers

3.4. Market dynamics

3.4.1. Drivers

3.4.1.1. Rise in prevalence of chronic pain

3.4.1.2. Increase in prevalence of constipation.

3.4.1.3. Rise in availability of effective drugs for constipation treatment

3.4.2. Restraints

3.4.2.1. Side effects associated with drugs.

3.4.2.2. Substitutional options available for idiopathic constipation.

3.4.3. Opportunities

3.4.3.1. Rise in number of adoptions of key strategies by market.

4.1. Overview

4.1.1. Market size and forecast

4.2. Mu-Opioid Receptor Antagonists

4.2.1. Key market trends, growth factors and opportunities

4.2.2. Market size and forecast, by region

4.2.3. Market share analysis by country

4.3. Laxative

4.3.1. Key market trends, growth factors and opportunities

4.3.2. Market size and forecast, by region

4.3.3. Market share analysis by country

4.4. Chloride Channel-2 Activator

4.4.1. Key market trends, growth factors and opportunities

4.4.2. Market size and forecast, by region

4.4.3. Market share analysis by country

4.5. Guanylate Cyclase-C (GC-C) Agonist

4.5.1. Key market trends, growth factors and opportunities

4.5.2. Market size and forecast, by region

4.5.3. Market share analysis by country

4.6. Others

4.6.1. Key market trends, growth factors and opportunities

4.6.2. Market size and forecast, by region

4.6.3. Market share analysis by country

5.1. Overview

5.1.1. Market size and forecast

5.2. Opioid-Induced Constipation

5.2.1. Key market trends, growth factors and opportunities

5.2.2. Market size and forecast, by region

5.2.3. Market share analysis by country

5.3. Chronic Idiopathic Constipation

5.3.1. Key market trends, growth factors and opportunities

5.3.2. Market size and forecast, by region

5.3.3. Market share analysis by country

5.4. Irritable Bowel Syndrome with Constipation

5.4.1. Key market trends, growth factors and opportunities

5.4.2. Market size and forecast, by region

5.4.3. Market share analysis by country

6.1. Overview

6.1.1. Market size and forecast

6.2. Prescribed Drugs

6.2.1. Key market trends, growth factors and opportunities

6.2.2. Market size and forecast, by region

6.2.3. Market share analysis by country

6.3. Over-the-Counter Drugs

6.3.1. Key market trends, growth factors and opportunities

6.3.2. Market size and forecast, by region

6.3.3. Market share analysis by country

7.1. Overview

7.1.1. Market size and forecast

7.2. Online Pharmacy

7.2.1. Key market trends, growth factors and opportunities

7.2.2. Market size and forecast, by region

7.2.3. Market share analysis by country

7.3. Drug Store and Retail Pharmacy

7.3.1. Key market trends, growth factors and opportunities

7.3.2. Market size and forecast, by region

7.3.3. Market share analysis by country

7.4. Others

7.4.1. Key market trends, growth factors and opportunities

7.4.2. Market size and forecast, by region

7.4.3. Market share analysis by country

8.1. Overview

8.1.1. Market size and forecast By Region

8.2. North America

8.2.1. Key market trends, growth factors and opportunities

8.2.2. Market size and forecast, by Product Type

8.2.3. Market size and forecast, by Disease Type

8.2.4. Market size and forecast, by Prescription Type

8.2.5. Market size and forecast, by Distribution Channel

8.2.6. Market size and forecast, by country

8.2.6.1. U.S.

8.2.6.1.1. Market size and forecast, by Product Type

8.2.6.1.2. Market size and forecast, by Disease Type

8.2.6.1.3. Market size and forecast, by Prescription Type

8.2.6.1.4. Market size and forecast, by Distribution Channel

8.2.6.2. Canada

8.2.6.2.1. Market size and forecast, by Product Type

8.2.6.2.2. Market size and forecast, by Disease Type

8.2.6.2.3. Market size and forecast, by Prescription Type

8.2.6.2.4. Market size and forecast, by Distribution Channel

8.2.6.3. Mexico

8.2.6.3.1. Market size and forecast, by Product Type

8.2.6.3.2. Market size and forecast, by Disease Type

8.2.6.3.3. Market size and forecast, by Prescription Type

8.2.6.3.4. Market size and forecast, by Distribution Channel

8.3. Europe

8.3.1. Key market trends, growth factors and opportunities

8.3.2. Market size and forecast, by Product Type

8.3.3. Market size and forecast, by Disease Type

8.3.4. Market size and forecast, by Prescription Type

8.3.5. Market size and forecast, by Distribution Channel

8.3.6. Market size and forecast, by country

8.3.6.1. Germany

8.3.6.1.1. Market size and forecast, by Product Type

8.3.6.1.2. Market size and forecast, by Disease Type

8.3.6.1.3. Market size and forecast, by Prescription Type

8.3.6.1.4. Market size and forecast, by Distribution Channel

8.3.6.2. France

8.3.6.2.1. Market size and forecast, by Product Type

8.3.6.2.2. Market size and forecast, by Disease Type

8.3.6.2.3. Market size and forecast, by Prescription Type

8.3.6.2.4. Market size and forecast, by Distribution Channel

8.3.6.3. UK

8.3.6.3.1. Market size and forecast, by Product Type

8.3.6.3.2. Market size and forecast, by Disease Type

8.3.6.3.3. Market size and forecast, by Prescription Type

8.3.6.3.4. Market size and forecast, by Distribution Channel

8.3.6.4. Italy

8.3.6.4.1. Market size and forecast, by Product Type

8.3.6.4.2. Market size and forecast, by Disease Type

8.3.6.4.3. Market size and forecast, by Prescription Type

8.3.6.4.4. Market size and forecast, by Distribution Channel

8.3.6.5. Spain

8.3.6.5.1. Market size and forecast, by Product Type

8.3.6.5.2. Market size and forecast, by Disease Type

8.3.6.5.3. Market size and forecast, by Prescription Type

8.3.6.5.4. Market size and forecast, by Distribution Channel

8.3.6.6. Rest of Europe

8.3.6.6.1. Market size and forecast, by Product Type

8.3.6.6.2. Market size and forecast, by Disease Type

8.3.6.6.3. Market size and forecast, by Prescription Type

8.3.6.6.4. Market size and forecast, by Distribution Channel

8.4. Asia-Pacific

8.4.1. Key market trends, growth factors and opportunities

8.4.2. Market size and forecast, by Product Type

8.4.3. Market size and forecast, by Disease Type

8.4.4. Market size and forecast, by Prescription Type

8.4.5. Market size and forecast, by Distribution Channel

8.4.6. Market size and forecast, by country

8.4.6.1. Japan

8.4.6.1.1. Market size and forecast, by Product Type

8.4.6.1.2. Market size and forecast, by Disease Type

8.4.6.1.3. Market size and forecast, by Prescription Type

8.4.6.1.4. Market size and forecast, by Distribution Channel

8.4.6.2. China

8.4.6.2.1. Market size and forecast, by Product Type

8.4.6.2.2. Market size and forecast, by Disease Type

8.4.6.2.3. Market size and forecast, by Prescription Type

8.4.6.2.4. Market size and forecast, by Distribution Channel

8.4.6.3. India

8.4.6.3.1. Market size and forecast, by Product Type

8.4.6.3.2. Market size and forecast, by Disease Type

8.4.6.3.3. Market size and forecast, by Prescription Type

8.4.6.3.4. Market size and forecast, by Distribution Channel

8.4.6.4. Australia

8.4.6.4.1. Market size and forecast, by Product Type

8.4.6.4.2. Market size and forecast, by Disease Type

8.4.6.4.3. Market size and forecast, by Prescription Type

8.4.6.4.4. Market size and forecast, by Distribution Channel

8.4.6.5. South Korea

8.4.6.5.1. Market size and forecast, by Product Type

8.4.6.5.2. Market size and forecast, by Disease Type

8.4.6.5.3. Market size and forecast, by Prescription Type

8.4.6.5.4. Market size and forecast, by Distribution Channel

8.4.6.6. Rest of Europe

8.4.6.6.1. Market size and forecast, by Product Type

8.4.6.6.2. Market size and forecast, by Disease Type

8.4.6.6.3. Market size and forecast, by Prescription Type

8.4.6.6.4. Market size and forecast, by Distribution Channel

8.5. LAMEA

8.5.1. Key market trends, growth factors and opportunities

8.5.2. Market size and forecast, by Product Type

8.5.3. Market size and forecast, by Disease Type

8.5.4. Market size and forecast, by Prescription Type

8.5.5. Market size and forecast, by Distribution Channel

8.5.6. Market size and forecast, by country

8.5.6.1. Brazil

8.5.6.1.1. Market size and forecast, by Product Type

8.5.6.1.2. Market size and forecast, by Disease Type

8.5.6.1.3. Market size and forecast, by Prescription Type

8.5.6.1.4. Market size and forecast, by Distribution Channel

8.5.6.2. South Africa,

8.5.6.2.1. Market size and forecast, by Product Type

8.5.6.2.2. Market size and forecast, by Disease Type

8.5.6.2.3. Market size and forecast, by Prescription Type

8.5.6.2.4. Market size and forecast, by Distribution Channel

8.5.6.3. Saudi Arabia

8.5.6.3.1. Market size and forecast, by Product Type

8.5.6.3.2. Market size and forecast, by Disease Type

8.5.6.3.3. Market size and forecast, by Prescription Type

8.5.6.3.4. Market size and forecast, by Distribution Channel

8.5.6.4. Rest of LAMEA

8.5.6.4.1. Market size and forecast, by Product Type

8.5.6.4.2. Market size and forecast, by Disease Type

8.5.6.4.3. Market size and forecast, by Prescription Type

8.5.6.4.4. Market size and forecast, by Distribution Channel

9.1. Introduction

9.2. Top winning strategies

9.3. Product Mapping of Top 10 Player

9.4. Competitive Dashboard

9.5. Competitive Heatmap

9.6. Top player positioning, 2022

10.1. Takeda Pharmaceutical Company Ltd.

10.1.1. Company overview

10.1.2. Key Executives

10.1.3. Company snapshot

10.1.4. Operating business segments

10.1.5. Product portfolio

10.1.6. Business performance

10.2. AbbVie Inc.

10.2.1. Company overview

10.2.2. Key Executives

10.2.3. Company snapshot

10.2.4. Operating business segments

10.2.5. Product portfolio

10.2.6. Business performance

10.2.7. Key strategic moves and developments

10.3. Abbott Laboratories

10.3.1. Company overview

10.3.2. Key Executives

10.3.3. Company snapshot

10.3.4. Operating business segments

10.3.5. Product portfolio

10.3.6. Business performance

10.4. Sanofi S.A.

10.4.1. Company overview

10.4.2. Key Executives

10.4.3. Company snapshot

10.4.4. Operating business segments

10.4.5. Product portfolio

10.4.6. Business performance

10.5. Bausch Health Companies Inc.

10.5.1. Company overview

10.5.2. Key Executives

10.5.3. Company snapshot

10.5.4. Operating business segments

10.5.5. Product portfolio

10.5.6. Business performance

10.5.7. Key strategic moves and developments

10.6. Bayer AG

10.6.1. Company overview

10.6.2. Key Executives

10.6.3. Company snapshot

10.6.4. Operating business segments

10.6.5. Product portfolio

10.6.6. Business performance

10.7. AstraZeneca plc

10.7.1. Company overview

10.7.2. Key Executives

10.7.3. Company snapshot

10.7.4. Operating business segments

10.7.5. Product portfolio

10.7.6. Business performance

10.8. Ironwood Pharmaceuticals, Inc.

10.8.1. Company overview

10.8.2. Key Executives

10.8.3. Company snapshot

10.8.4. Operating business segments

10.8.5. Product portfolio

10.8.6. Business performance

10.8.7. Key strategic moves and developments

10.9. Prestige Consumer Healthcare Inc.

10.9.1. Company overview

10.9.2. Key Executives

10.9.3. Company snapshot

10.9.4. Operating business segments

10.9.5. Product portfolio

10.9.6. Business performance

10.10. Ardelyx Inc.

10.10.1. Company overview

10.10.2. Key Executives

10.10.3. Company snapshot

10.10.4. Operating business segments

10.10.5. Product portfolio

10.10.6. Key strategic moves and development

LIST OF TABLES

TABLE 01. GLOBAL CONSTIPATION TREATMENT MARKET, BY PRODUCT TYPE, 2022-2032 ($MILLION)

TABLE 02. CONSTIPATION TREATMENT MARKET FOR MU-OPIOID RECEPTOR ANTAGONISTS, BY REGION, 2022-2032 ($MILLION)

TABLE 03. CONSTIPATION TREATMENT MARKET FOR LAXATIVE, BY REGION, 2022-2032 ($MILLION)

TABLE 04. CONSTIPATION TREATMENT MARKET FOR CHLORIDE CHANNEL-2 ACTIVATOR, BY REGION, 2022-2032 ($MILLION)

TABLE 05. CONSTIPATION TREATMENT MARKET FOR GUANYLATE CYCLASE-C (GC-C) AGONIST, BY REGION, 2022-2032 ($MILLION)

TABLE 06. CONSTIPATION TREATMENT MARKET FOR OTHERS, BY REGION, 2022-2032 ($MILLION)

TABLE 07. GLOBAL CONSTIPATION TREATMENT MARKET, BY DISEASE TYPE, 2022-2032 ($MILLION)

TABLE 08. CONSTIPATION TREATMENT MARKET FOR OPIOID-INDUCED CONSTIPATION, BY REGION, 2022-2032 ($MILLION)

TABLE 09. CONSTIPATION TREATMENT MARKET FOR CHRONIC IDIOPATHIC CONSTIPATION, BY REGION, 2022-2032 ($MILLION)

TABLE 10. CONSTIPATION TREATMENT MARKET FOR IRRITABLE BOWEL SYNDROME WITH CONSTIPATION, BY REGION, 2022-2032 ($MILLION)

TABLE 11. GLOBAL CONSTIPATION TREATMENT MARKET, BY PRESCRIPTION TYPE, 2022-2032 ($MILLION)

TABLE 12. CONSTIPATION TREATMENT MARKET FOR PRESCRIBED DRUGS, BY REGION, 2022-2032 ($MILLION)

TABLE 13. CONSTIPATION TREATMENT MARKET FOR OVER-THE-COUNTER DRUGS, BY REGION, 2022-2032 ($MILLION)

TABLE 14. GLOBAL CONSTIPATION TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)

TABLE 15. CONSTIPATION TREATMENT MARKET FOR ONLINE PHARMACY, BY REGION, 2022-2032 ($MILLION)

TABLE 16. CONSTIPATION TREATMENT MARKET FOR DRUG STORE AND RETAIL PHARMACY, BY REGION, 2022-2032 ($MILLION)

TABLE 17. CONSTIPATION TREATMENT MARKET FOR OTHERS, BY REGION, 2022-2032 ($MILLION)

TABLE 18. CONSTIPATION TREATMENT MARKET, BY REGION, 2022-2032 ($MILLION)

TABLE 19. NORTH AMERICA CONSTIPATION TREATMENT MARKET, BY PRODUCT TYPE, 2022-2032 ($MILLION)

TABLE 20. NORTH AMERICA CONSTIPATION TREATMENT MARKET, BY DISEASE TYPE, 2022-2032 ($MILLION)

TABLE 21. NORTH AMERICA CONSTIPATION TREATMENT MARKET, BY PRESCRIPTION TYPE, 2022-2032 ($MILLION)

TABLE 22. NORTH AMERICA CONSTIPATION TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)

TABLE 23. NORTH AMERICA CONSTIPATION TREATMENT MARKET, BY COUNTRY, 2022-2032 ($MILLION)

TABLE 24. U.S. CONSTIPATION TREATMENT MARKET, BY PRODUCT TYPE, 2022-2032 ($MILLION)

TABLE 25. U.S. CONSTIPATION TREATMENT MARKET, BY DISEASE TYPE, 2022-2032 ($MILLION)

TABLE 26. U.S. CONSTIPATION TREATMENT MARKET, BY PRESCRIPTION TYPE, 2022-2032 ($MILLION)

TABLE 27. U.S. CONSTIPATION TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)

TABLE 28. CANADA CONSTIPATION TREATMENT MARKET, BY PRODUCT TYPE, 2022-2032 ($MILLION)

TABLE 29. CANADA CONSTIPATION TREATMENT MARKET, BY DISEASE TYPE, 2022-2032 ($MILLION)

TABLE 30. CANADA CONSTIPATION TREATMENT MARKET, BY PRESCRIPTION TYPE, 2022-2032 ($MILLION)

TABLE 31. CANADA CONSTIPATION TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)

TABLE 32. MEXICO CONSTIPATION TREATMENT MARKET, BY PRODUCT TYPE, 2022-2032 ($MILLION)

TABLE 33. MEXICO CONSTIPATION TREATMENT MARKET, BY DISEASE TYPE, 2022-2032 ($MILLION)

TABLE 34. MEXICO CONSTIPATION TREATMENT MARKET, BY PRESCRIPTION TYPE, 2022-2032 ($MILLION)

TABLE 35. MEXICO CONSTIPATION TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)

TABLE 36. EUROPE CONSTIPATION TREATMENT MARKET, BY PRODUCT TYPE, 2022-2032 ($MILLION)

TABLE 37. EUROPE CONSTIPATION TREATMENT MARKET, BY DISEASE TYPE, 2022-2032 ($MILLION)

TABLE 38. EUROPE CONSTIPATION TREATMENT MARKET, BY PRESCRIPTION TYPE, 2022-2032 ($MILLION)

TABLE 39. EUROPE CONSTIPATION TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)

TABLE 40. EUROPE CONSTIPATION TREATMENT MARKET, BY COUNTRY, 2022-2032 ($MILLION)

TABLE 41. GERMANY CONSTIPATION TREATMENT MARKET, BY PRODUCT TYPE, 2022-2032 ($MILLION)

TABLE 42. GERMANY CONSTIPATION TREATMENT MARKET, BY DISEASE TYPE, 2022-2032 ($MILLION)

TABLE 43. GERMANY CONSTIPATION TREATMENT MARKET, BY PRESCRIPTION TYPE, 2022-2032 ($MILLION)

TABLE 44. GERMANY CONSTIPATION TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)

TABLE 45. FRANCE CONSTIPATION TREATMENT MARKET, BY PRODUCT TYPE, 2022-2032 ($MILLION)

TABLE 46. FRANCE CONSTIPATION TREATMENT MARKET, BY DISEASE TYPE, 2022-2032 ($MILLION)

TABLE 47. FRANCE CONSTIPATION TREATMENT MARKET, BY PRESCRIPTION TYPE, 2022-2032 ($MILLION)

TABLE 48. FRANCE CONSTIPATION TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)

TABLE 49. UK CONSTIPATION TREATMENT MARKET, BY PRODUCT TYPE, 2022-2032 ($MILLION)

TABLE 50. UK CONSTIPATION TREATMENT MARKET, BY DISEASE TYPE, 2022-2032 ($MILLION)

TABLE 51. UK CONSTIPATION TREATMENT MARKET, BY PRESCRIPTION TYPE, 2022-2032 ($MILLION)

TABLE 52. UK CONSTIPATION TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)

TABLE 53. ITALY CONSTIPATION TREATMENT MARKET, BY PRODUCT TYPE, 2022-2032 ($MILLION)

TABLE 54. ITALY CONSTIPATION TREATMENT MARKET, BY DISEASE TYPE, 2022-2032 ($MILLION)

TABLE 55. ITALY CONSTIPATION TREATMENT MARKET, BY PRESCRIPTION TYPE, 2022-2032 ($MILLION)

TABLE 56. ITALY CONSTIPATION TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)

TABLE 57. SPAIN CONSTIPATION TREATMENT MARKET, BY PRODUCT TYPE, 2022-2032 ($MILLION)

TABLE 58. SPAIN CONSTIPATION TREATMENT MARKET, BY DISEASE TYPE, 2022-2032 ($MILLION)

TABLE 59. SPAIN CONSTIPATION TREATMENT MARKET, BY PRESCRIPTION TYPE, 2022-2032 ($MILLION)

TABLE 60. SPAIN CONSTIPATION TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)

TABLE 61. REST OF EUROPE CONSTIPATION TREATMENT MARKET, BY PRODUCT TYPE, 2022-2032 ($MILLION)

TABLE 62. REST OF EUROPE CONSTIPATION TREATMENT MARKET, BY DISEASE TYPE, 2022-2032 ($MILLION)

TABLE 63. REST OF EUROPE CONSTIPATION TREATMENT MARKET, BY PRESCRIPTION TYPE, 2022-2032 ($MILLION)

TABLE 64. REST OF EUROPE CONSTIPATION TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)

TABLE 65. ASIA-PACIFIC CONSTIPATION TREATMENT MARKET, BY PRODUCT TYPE, 2022-2032 ($MILLION)

TABLE 66. ASIA-PACIFIC CONSTIPATION TREATMENT MARKET, BY DISEASE TYPE, 2022-2032 ($MILLION)

TABLE 67. ASIA-PACIFIC CONSTIPATION TREATMENT MARKET, BY PRESCRIPTION TYPE, 2022-2032 ($MILLION)

TABLE 68. ASIA-PACIFIC CONSTIPATION TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)

TABLE 69. ASIA-PACIFIC CONSTIPATION TREATMENT MARKET, BY COUNTRY, 2022-2032 ($MILLION)

TABLE 70. JAPAN CONSTIPATION TREATMENT MARKET, BY PRODUCT TYPE, 2022-2032 ($MILLION)

TABLE 71. JAPAN CONSTIPATION TREATMENT MARKET, BY DISEASE TYPE, 2022-2032 ($MILLION)

TABLE 72. JAPAN CONSTIPATION TREATMENT MARKET, BY PRESCRIPTION TYPE, 2022-2032 ($MILLION)

TABLE 73. JAPAN CONSTIPATION TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)

TABLE 74. CHINA CONSTIPATION TREATMENT MARKET, BY PRODUCT TYPE, 2022-2032 ($MILLION)

TABLE 75. CHINA CONSTIPATION TREATMENT MARKET, BY DISEASE TYPE, 2022-2032 ($MILLION)

TABLE 76. CHINA CONSTIPATION TREATMENT MARKET, BY PRESCRIPTION TYPE, 2022-2032 ($MILLION)

TABLE 77. CHINA CONSTIPATION TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)

TABLE 78. INDIA CONSTIPATION TREATMENT MARKET, BY PRODUCT TYPE, 2022-2032 ($MILLION)

TABLE 79. INDIA CONSTIPATION TREATMENT MARKET, BY DISEASE TYPE, 2022-2032 ($MILLION)

TABLE 80. INDIA CONSTIPATION TREATMENT MARKET, BY PRESCRIPTION TYPE, 2022-2032 ($MILLION)

TABLE 81. INDIA CONSTIPATION TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)

TABLE 82. AUSTRALIA CONSTIPATION TREATMENT MARKET, BY PRODUCT TYPE, 2022-2032 ($MILLION)

TABLE 83. AUSTRALIA CONSTIPATION TREATMENT MARKET, BY DISEASE TYPE, 2022-2032 ($MILLION)

TABLE 84. AUSTRALIA CONSTIPATION TREATMENT MARKET, BY PRESCRIPTION TYPE, 2022-2032 ($MILLION)

TABLE 85. AUSTRALIA CONSTIPATION TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)

TABLE 86. SOUTH KOREA CONSTIPATION TREATMENT MARKET, BY PRODUCT TYPE, 2022-2032 ($MILLION)

TABLE 87. SOUTH KOREA CONSTIPATION TREATMENT MARKET, BY DISEASE TYPE, 2022-2032 ($MILLION)

TABLE 88. SOUTH KOREA CONSTIPATION TREATMENT MARKET, BY PRESCRIPTION TYPE, 2022-2032 ($MILLION)

TABLE 89. SOUTH KOREA CONSTIPATION TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)

TABLE 90. REST OF EUROPE CONSTIPATION TREATMENT MARKET, BY PRODUCT TYPE, 2022-2032 ($MILLION)

TABLE 91. REST OF EUROPE CONSTIPATION TREATMENT MARKET, BY DISEASE TYPE, 2022-2032 ($MILLION)

TABLE 92. REST OF EUROPE CONSTIPATION TREATMENT MARKET, BY PRESCRIPTION TYPE, 2022-2032 ($MILLION)

TABLE 93. REST OF EUROPE CONSTIPATION TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)

TABLE 94. LAMEA CONSTIPATION TREATMENT MARKET, BY PRODUCT TYPE, 2022-2032 ($MILLION)

TABLE 95. LAMEA CONSTIPATION TREATMENT MARKET, BY DISEASE TYPE, 2022-2032 ($MILLION)

TABLE 96. LAMEA CONSTIPATION TREATMENT MARKET, BY PRESCRIPTION TYPE, 2022-2032 ($MILLION)

TABLE 97. LAMEA CONSTIPATION TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)

TABLE 98. LAMEA CONSTIPATION TREATMENT MARKET, BY COUNTRY, 2022-2032 ($MILLION)

TABLE 99. BRAZIL CONSTIPATION TREATMENT MARKET, BY PRODUCT TYPE, 2022-2032 ($MILLION)

TABLE 100. BRAZIL CONSTIPATION TREATMENT MARKET, BY DISEASE TYPE, 2022-2032 ($MILLION)

TABLE 101. BRAZIL CONSTIPATION TREATMENT MARKET, BY PRESCRIPTION TYPE, 2022-2032 ($MILLION)

TABLE 102. BRAZIL CONSTIPATION TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)

TABLE 103. SOUTH AFRICA, CONSTIPATION TREATMENT MARKET, BY PRODUCT TYPE, 2022-2032 ($MILLION)

TABLE 104. SOUTH AFRICA, CONSTIPATION TREATMENT MARKET, BY DISEASE TYPE, 2022-2032 ($MILLION)

TABLE 105. SOUTH AFRICA, CONSTIPATION TREATMENT MARKET, BY PRESCRIPTION TYPE, 2022-2032 ($MILLION)

TABLE 106. SOUTH AFRICA, CONSTIPATION TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)

TABLE 107. SAUDI ARABIA CONSTIPATION TREATMENT MARKET, BY PRODUCT TYPE, 2022-2032 ($MILLION)

TABLE 108. SAUDI ARABIA CONSTIPATION TREATMENT MARKET, BY DISEASE TYPE, 2022-2032 ($MILLION)

TABLE 109. SAUDI ARABIA CONSTIPATION TREATMENT MARKET, BY PRESCRIPTION TYPE, 2022-2032 ($MILLION)

TABLE 110. SAUDI ARABIA CONSTIPATION TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)

TABLE 111. REST OF LAMEA CONSTIPATION TREATMENT MARKET, BY PRODUCT TYPE, 2022-2032 ($MILLION)

TABLE 112. REST OF LAMEA CONSTIPATION TREATMENT MARKET, BY DISEASE TYPE, 2022-2032 ($MILLION)

TABLE 113. REST OF LAMEA CONSTIPATION TREATMENT MARKET, BY PRESCRIPTION TYPE, 2022-2032 ($MILLION)

TABLE 114. REST OF LAMEA CONSTIPATION TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)

TABLE 115. TAKEDA PHARMACEUTICAL COMPANY LTD.: KEY EXECUTIVES

TABLE 116. TAKEDA PHARMACEUTICAL COMPANY LTD.: COMPANY SNAPSHOT

TABLE 117. TAKEDA PHARMACEUTICAL COMPANY LTD.: PRODUCT SEGMENTS

TABLE 118. TAKEDA PHARMACEUTICAL COMPANY LTD.: PRODUCT PORTFOLIO

TABLE 119. ABBVIE INC.: KEY EXECUTIVES

TABLE 120. ABBVIE INC.: COMPANY SNAPSHOT

TABLE 121. ABBVIE INC.: PRODUCT SEGMENTS

TABLE 122. ABBVIE INC.: PRODUCT PORTFOLIO

TABLE 123. ABBVIE INC.: KEY STRATERGIES

TABLE 124. ABBOTT LABORATORIES: KEY EXECUTIVES

TABLE 125. ABBOTT LABORATORIES: COMPANY SNAPSHOT

TABLE 126. ABBOTT LABORATORIES: PRODUCT SEGMENTS

TABLE 127. ABBOTT LABORATORIES: PRODUCT PORTFOLIO

TABLE 128. SANOFI S.A.: KEY EXECUTIVES

TABLE 129. SANOFI S.A.: COMPANY SNAPSHOT

TABLE 130. SANOFI S.A.: PRODUCT SEGMENTS

TABLE 131. SANOFI S.A.: PRODUCT PORTFOLIO

TABLE 132. BAUSCH HEALTH COMPANIES INC.: KEY EXECUTIVES

TABLE 133. BAUSCH HEALTH COMPANIES INC.: COMPANY SNAPSHOT

TABLE 134. BAUSCH HEALTH COMPANIES INC.: PRODUCT SEGMENTS

TABLE 135. BAUSCH HEALTH COMPANIES INC.: PRODUCT PORTFOLIO

TABLE 136. BAUSCH HEALTH COMPANIES INC.: KEY STRATERGIES

TABLE 137. BAYER AG: KEY EXECUTIVES

TABLE 138. BAYER AG: COMPANY SNAPSHOT

TABLE 139. BAYER AG: PRODUCT SEGMENTS

TABLE 140. BAYER AG: PRODUCT PORTFOLIO

TABLE 141. ASTRAZENECA PLC: KEY EXECUTIVES

TABLE 142. ASTRAZENECA PLC: COMPANY SNAPSHOT

TABLE 143. ASTRAZENECA PLC: PRODUCT SEGMENTS

TABLE 144. ASTRAZENECA PLC: PRODUCT PORTFOLIO

TABLE 145. IRONWOOD PHARMACEUTICALS, INC.: KEY EXECUTIVES

TABLE 146. IRONWOOD PHARMACEUTICALS, INC.: COMPANY SNAPSHOT

TABLE 147. IRONWOOD PHARMACEUTICALS, INC.: PRODUCT SEGMENTS

TABLE 148. IRONWOOD PHARMACEUTICALS, INC.: PRODUCT PORTFOLIO

TABLE 149. IRONWOOD PHARMACEUTICALS, INC.: KEY STRATERGIES

TABLE 150. PRESTIGE CONSUMER HEALTHCARE INC.: KEY EXECUTIVES

TABLE 151. PRESTIGE CONSUMER HEALTHCARE INC.: COMPANY SNAPSHOT

TABLE 152. PRESTIGE CONSUMER HEALTHCARE INC.: PRODUCT SEGMENTS

TABLE 153. PRESTIGE CONSUMER HEALTHCARE INC.: PRODUCT PORTFOLIO

TABLE 154. ARDELYX INC.: KEY EXECUTIVES

TABLE 155. ARDELYX INC.: COMPANY SNAPSHOT

TABLE 156. ARDELYX INC.: PRODUCT SEGMENTS

TABLE 157. ARDELYX INC.: PRODUCT PORTFOLIO

TABLE 158. ARDELYX INC.: KEY STRATERGIES LIST OF FIGURES

FIGURE 01. CONSTIPATION TREATMENT MARKET, 2022-2032

FIGURE 02. SEGMENTATION OF CONSTIPATION TREATMENT MARKET,2022-2032

FIGURE 03. TOP INVESTMENT POCKETS IN CONSTIPATION TREATMENT MARKET (2023-2032)

FIGURE 04. LOW BARGAINING POWER OF SUPPLIERS

FIGURE 05. LOW THREAT OF NEW ENTRANTS

FIGURE 06. LOW THREAT OF SUBSTITUTES

FIGURE 07. LOW INTENSITY OF RIVALRY

FIGURE 08. LOW BARGAINING POWER OF BUYERS

FIGURE 09. GLOBAL CONSTIPATION TREATMENT MARKET:DRIVERS, RESTRAINTS AND OPPORTUNITIES

FIGURE 10. CONSTIPATION TREATMENT MARKET, BY PRODUCT TYPE, 2022 AND 2032(%)

FIGURE 11. COMPARATIVE SHARE ANALYSIS OF CONSTIPATION TREATMENT MARKET FOR MU-OPIOID RECEPTOR ANTAGONISTS, BY COUNTRY 2022 AND 2032(%)

FIGURE 12. COMPARATIVE SHARE ANALYSIS OF CONSTIPATION TREATMENT MARKET FOR LAXATIVE, BY COUNTRY 2022 AND 2032(%)

FIGURE 13. COMPARATIVE SHARE ANALYSIS OF CONSTIPATION TREATMENT MARKET FOR CHLORIDE CHANNEL-2 ACTIVATOR, BY COUNTRY 2022 AND 2032(%)

FIGURE 14. COMPARATIVE SHARE ANALYSIS OF CONSTIPATION TREATMENT MARKET FOR GUANYLATE CYCLASE-C (GC-C) AGONIST, BY COUNTRY 2022 AND 2032(%)

FIGURE 15. COMPARATIVE SHARE ANALYSIS OF CONSTIPATION TREATMENT MARKET FOR OTHERS, BY COUNTRY 2022 AND 2032(%)

FIGURE 16. CONSTIPATION TREATMENT MARKET, BY DISEASE TYPE, 2022 AND 2032(%)

FIGURE 17. COMPARATIVE SHARE ANALYSIS OF CONSTIPATION TREATMENT MARKET FOR OPIOID-INDUCED CONSTIPATION, BY COUNTRY 2022 AND 2032(%)

FIGURE 18. COMPARATIVE SHARE ANALYSIS OF CONSTIPATION TREATMENT MARKET FOR CHRONIC IDIOPATHIC CONSTIPATION, BY COUNTRY 2022 AND 2032(%)

FIGURE 19. COMPARATIVE SHARE ANALYSIS OF CONSTIPATION TREATMENT MARKET FOR IRRITABLE BOWEL SYNDROME WITH CONSTIPATION, BY COUNTRY 2022 AND 2032(%)

FIGURE 20. CONSTIPATION TREATMENT MARKET, BY PRESCRIPTION TYPE, 2022 AND 2032(%)

FIGURE 21. COMPARATIVE SHARE ANALYSIS OF CONSTIPATION TREATMENT MARKET FOR PRESCRIBED DRUGS, BY COUNTRY 2022 AND 2032(%)

FIGURE 22. COMPARATIVE SHARE ANALYSIS OF CONSTIPATION TREATMENT MARKET FOR OVER-THE-COUNTER DRUGS, BY COUNTRY 2022 AND 2032(%)

FIGURE 23. CONSTIPATION TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022 AND 2032(%)

FIGURE 24. COMPARATIVE SHARE ANALYSIS OF CONSTIPATION TREATMENT MARKET FOR ONLINE PHARMACY, BY COUNTRY 2022 AND 2032(%)

FIGURE 25. COMPARATIVE SHARE ANALYSIS OF CONSTIPATION TREATMENT MARKET FOR DRUG STORE AND RETAIL PHARMACY, BY COUNTRY 2022 AND 2032(%)

FIGURE 26. COMPARATIVE SHARE ANALYSIS OF CONSTIPATION TREATMENT MARKET FOR OTHERS, BY COUNTRY 2022 AND 2032(%)

FIGURE 27. CONSTIPATION TREATMENT MARKET BY REGION, 2022 AND 2032(%)

FIGURE 28. U.S. CONSTIPATION TREATMENT MARKET, 2022-2032 ($MILLION)

FIGURE 29. CANADA CONSTIPATION TREATMENT MARKET, 2022-2032 ($MILLION)

FIGURE 30. MEXICO CONSTIPATION TREATMENT MARKET, 2022-2032 ($MILLION)

FIGURE 31. GERMANY CONSTIPATION TREATMENT MARKET, 2022-2032 ($MILLION)

FIGURE 32. FRANCE CONSTIPATION TREATMENT MARKET, 2022-2032 ($MILLION)

FIGURE 33. UK CONSTIPATION TREATMENT MARKET, 2022-2032 ($MILLION)

FIGURE 34. ITALY CONSTIPATION TREATMENT MARKET, 2022-2032 ($MILLION)

FIGURE 35. SPAIN CONSTIPATION TREATMENT MARKET, 2022-2032 ($MILLION)

FIGURE 36. REST OF EUROPE CONSTIPATION TREATMENT MARKET, 2022-2032 ($MILLION)

FIGURE 37. JAPAN CONSTIPATION TREATMENT MARKET, 2022-2032 ($MILLION)

FIGURE 38. CHINA CONSTIPATION TREATMENT MARKET, 2022-2032 ($MILLION)

FIGURE 39. INDIA CONSTIPATION TREATMENT MARKET, 2022-2032 ($MILLION)

FIGURE 40. AUSTRALIA CONSTIPATION TREATMENT MARKET, 2022-2032 ($MILLION)

FIGURE 41. SOUTH KOREA CONSTIPATION TREATMENT MARKET, 2022-2032 ($MILLION)

FIGURE 42. REST OF EUROPE CONSTIPATION TREATMENT MARKET, 2022-2032 ($MILLION)

FIGURE 43. BRAZIL CONSTIPATION TREATMENT MARKET, 2022-2032 ($MILLION)

FIGURE 44. SOUTH AFRICA, CONSTIPATION TREATMENT MARKET, 2022-2032 ($MILLION)

FIGURE 45. SAUDI ARABIA CONSTIPATION TREATMENT MARKET, 2022-2032 ($MILLION)

FIGURE 46. REST OF LAMEA CONSTIPATION TREATMENT MARKET, 2022-2032 ($MILLION)

FIGURE 47. TOP WINNING STRATEGIES, BY YEAR (2022-2023)

FIGURE 48. TOP WINNING STRATEGIES, BY DEVELOPMENT (2022-2023)

FIGURE 49. TOP WINNING STRATEGIES, BY COMPANY (2022-2023)

FIGURE 50. PRODUCT MAPPING OF TOP 10 PLAYERS

FIGURE 51. COMPETITIVE DASHBOARD

FIGURE 52. COMPETITIVE HEATMAP: CONSTIPATION TREATMENT MARKET

FIGURE 53. TOP PLAYER POSITIONING, 2022

FIGURE 54. TAKEDA PHARMACEUTICAL COMPANY LTD.: NET REVENUE, 2020-2022 ($MILLION)

FIGURE 55. TAKEDA PHARMACEUTICAL COMPANY LTD.: REVENUE SHARE BY REGION, 2022 (%)

FIGURE 56. ABBVIE INC.: NET REVENUE, 2020-2022 ($MILLION)

FIGURE 57. ABBVIE INC.: REVENUE SHARE BY SEGMENT, 2022 (%)

FIGURE 58. ABBVIE INC.: REVENUE SHARE BY REGION, 2022 (%)

FIGURE 59. ABBOTT LABORATORIES: NET SALES, 2020-2022 ($MILLION)

FIGURE 60. ABBOTT LABORATORIES: REVENUE SHARE BY SEGMENT, 2022 (%)

FIGURE 61. ABBOTT LABORATORIES: REVENUE SHARE BY REGION, 2022 (%)

FIGURE 62. SANOFI S.A.: NET SALES, 2020-2022 ($MILLION)

FIGURE 63. SANOFI S.A.: REVENUE SHARE BY SEGMENT, 2022 (%)

FIGURE 64. SANOFI S.A.: REVENUE SHARE BY REGION, 2022 (%)

FIGURE 65. BAUSCH HEALTH COMPANIES INC.: NET REVENUE, 2020-2022 ($MILLION)

FIGURE 66. BAUSCH HEALTH COMPANIES INC.: REVENUE SHARE BY SEGMENT, 2022 (%)

FIGURE 67. BAUSCH HEALTH COMPANIES INC.: REVENUE SHARE BY REGION, 2022 (%)

FIGURE 68. BAYER AG: NET SALES, 2020-2022 ($MILLION)

FIGURE 69. BAYER AG: REVENUE SHARE BY SEGMENT, 2022 (%)

FIGURE 70. BAYER AG: REVENUE SHARE BY REGION, 2022 (%)

FIGURE 71. ASTRAZENECA PLC: NET SALES, 2020-2022 ($MILLION)

FIGURE 72. ASTRAZENECA PLC: REVENUE SHARE BY REGION, 2022 (%)

FIGURE 73. IRONWOOD PHARMACEUTICALS, INC.: NET REVENUE, 2020-2022 ($MILLION)

FIGURE 74. IRONWOOD PHARMACEUTICALS, INC.: RESEARCH & DEVELOPMENT EXPENDITURE, 2020-2022 ($MILLION)

FIGURE 75. PRESTIGE CONSUMER HEALTHCARE INC.: NET SALES, 2020-2022 ($MILLION)

FIGURE 76. PRESTIGE CONSUMER HEALTHCARE INC.: REVENUE SHARE BY SEGMENT, 2021 (%)

FIGURE 77. PRESTIGE CONSUMER HEALTHCARE INC.: REVENUE SHARE BY REGION, 2021 (%